„”
Funding authority | Programme | Title | Period |
---|---|---|---|
SPRIN-D | Ein Quantensprung für neue antivirale Wirkstoffe | MucBoost (D. Lauster, B. Kaufer, J. Trimpert/FU Berlin, Chr. Hackenberger/FMP, Chr. Sieben/HZI, P. Boisguerin/Inserm, and M. Hittinger/PharmBioTec) | 11.2021 - 10.2023 |
Leibniz Association | Leibniz-Transfer | Selective depletion of plasma cells secreting pathogenic autoantibodies in chronic autoimmune diseases - a potentially curative therapeutic approach (F. Hiepe/Charité & DRFZ, A. Meisel/Charité, Chr. Hackenberger/FMP) | 01.2021 - 12.2023 |
Crowdfunding | www.gofundme.com | Development of an enzyme replacement therapy for the treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis (M. Dathe/FMP and H. Traupe/WWU) | Ongoing |
Leibniz Association | Leibniz-Transfer | Cystein‐selective bioconjugation for next generation antibody drug conjugates (Chr. Hackenberger/FMP) | 03.2018 - 12.2022 |
Federal Ministry of Education and Research (BMBF) | Targetvalidierung für die pharmazeutische Wirkstoffentwicklung | Evaluating Ena/VASP as a novel relevant drug target for treatment of cancer metastasis (R. Kühne/FMP and H.-G. Schmalz/University of Cologne) | 01.2018 - 04.2020 |
Bavarian Ministry of Economic Affairs and Media, Energy and Technology | m4 Award | Development of a Tubulis Technologies proprietary ADC for Acute Myeloid Leukemia treatment (Jonas Helma-Smets, Dominik Schumacher, Heinrich Leonhardt/LMU and Christian Hackenberger/FMP) | 01.2018 - 12.2019 |
Federal Ministry for Economic Affairs and Energy (BMWi) | EXIST Forschungstransfer I | Tubulis Technologies, a pre-start-up project affiliated with the Ludwig Maximilians University Munich (LMU, Jonas Helma-Smets, Dominik Schumacher, Heinrich Leonhardt) and the FMP (Christian Hackenberger) | 04.2017 - 09.2019 |